Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,129 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Natriuretic peptides and integrated risk assessment for cardiovascular disease: an individual-participant-data meta-analysis.
Natriuretic Peptides Studies Collaboration, Willeit P, Kaptoge S, Welsh P, Butterworth AS, Chowdhury R, Spackman SA, Pennells L, Gao P, Burgess S, Freitag DF, Sweeting M, Wood AM, Cook NR, Judd S, Trompet S, Nambi V, Olsen MH, Everett BM, Kee F, Ärnlöv J, Salomaa V, Levy D, Kauhanen J, Laukkanen JA, Kavousi M, Ninomiya T, Casas JP, Daniels LB, Lind L, Kistorp CN, Rosenberg J, Mueller T, Rubattu S, Panagiotakos DB, Franco OH, de Lemos JA, Luchner A, Kizer JR, Kiechl S, Salonen JT, Goya Wannamethee S, de Boer RA, Nordestgaard BG, Andersson J, Jørgensen T, Melander O, Ballantyne ChM, DeFilippi Ch, Ridker PM, Cushman M, Rosamond WD, Thompson SG, Gudnason V, Sattar N, Danesh J, Di Angelantonio E. Natriuretic Peptides Studies Collaboration, et al. Among authors: nordestgaard bg. Lancet Diabetes Endocrinol. 2016 Oct;4(10):840-9. doi: 10.1016/S2213-8587(16)30196-6. Epub 2016 Sep 3. Lancet Diabetes Endocrinol. 2016. PMID: 27599814 Free PMC article.
The Emerging Risk Factors Collaboration: analysis of individual data on lipid, inflammatory and other markers in over 1.1 million participants in 104 prospective studies of cardiovascular diseases.
Emerging Risk Factors Collaboration; Danesh J, Erqou S, Walker M, Thompson SG, Tipping R, Ford C, Pressel S, Walldius G, Jungner I, Folsom AR, Chambless LE, Knuiman M, Whincup PH, Wannamethee SG, Morris RW, Willeit J, Kiechl S, Santer P, Mayr A, Wald N, Ebrahim S, Lawlor DA, Yarnell JW, Gallacher J, Casiglia E, Tikhonoff V, Nietert PJ, Sutherland SE, Bachman DL, Keil JE, Cushman M, Psaty BM, Tracy RP, Tybjaerg-Hansen A, Nordestgaard BG, Frikke-Schmidt R, Giampaoli S, Palmieri L, Panico S, Vanuzzo D, Pilotto L, Simons L, McCallum J, Friedlander Y, Fowkes FG, Lee AJ, Smith FB, Taylor J, Guralnik J, Phillips C, Wallace R, Blazer D, Khaw KT, Jansson JH, Donfrancesco C, Salomaa V, Harald K, Jousilahti P, Vartiainen E, Woodward M, D'Agostino RB, Wolf PA, Vasan RS, Pencina MJ, Bladbjerg EM, Jorgensen T, Moller L, Jespersen J, Dankner R, Chetrit A, Lubin F, Rosengren A, Wilhelmsen L, Lappas G, Eriksson H, Bjorkelund C, Cremer P, Nagel D, Tilvis R, Strandberg T, Rodriguez B, Bouter LM, Heine RJ, Dekker JM, Nijpels G, Stehouwer CD, Rimm E, Pai J, Sato S, Iso H, Kitamura A, Noda H, Goldbourt U, Salomaa V, Salonen JT, Nyyssönen K, Tuomainen TP, Deeg D, Poppelaars JL, Meade T, Cooper J,… See abstract for full author list ➔ Emerging Risk Factors Collaboration, et al. Among authors: nordestgaard bg. Eur J Epidemiol. 2007;22(12):839-69. doi: 10.1007/s10654-007-9165-7. Epub 2007 Sep 18. Eur J Epidemiol. 2007. PMID: 17876711
Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial.
Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ, Koenig W, Libby P, Lorenzatti AJ, Macfadyen JG, Nordestgaard BG, Shepherd J, Willerson JT, Glynn RJ; JUPITER Trial Study Group. Ridker PM, et al. Among authors: nordestgaard bg. Lancet. 2009 Apr 4;373(9670):1175-82. doi: 10.1016/S0140-6736(09)60447-5. Epub 2009 Mar 28. Lancet. 2009. PMID: 19329177 Clinical Trial.
Major lipids, apolipoproteins, and risk of vascular disease.
Emerging Risk Factors Collaboration; Di Angelantonio E, Sarwar N, Perry P, Kaptoge S, Ray KK, Thompson A, Wood AM, Lewington S, Sattar N, Packard CJ, Collins R, Thompson SG, Danesh J. Emerging Risk Factors Collaboration, et al. JAMA. 2009 Nov 11;302(18):1993-2000. doi: 10.1001/jama.2009.1619. JAMA. 2009. PMID: 19903920 Free PMC article.
Rosuvastatin for primary prevention in older persons with elevated C-reactive protein and low to average low-density lipoprotein cholesterol levels: exploratory analysis of a randomized trial.
Glynn RJ, Koenig W, Nordestgaard BG, Shepherd J, Ridker PM. Glynn RJ, et al. Among authors: nordestgaard bg. Ann Intern Med. 2010 Apr 20;152(8):488-96, W174. doi: 10.7326/0003-4819-152-8-201004200-00005. Ann Intern Med. 2010. PMID: 20404379 Free PMC article. Clinical Trial.
Triglyceride-mediated pathways and coronary disease: collaborative analysis of 101 studies.
Triglyceride Coronary Disease Genetics Consortium and Emerging Risk Factors Collaboration; Sarwar N, Sandhu MS, Ricketts SL, Butterworth AS, Di Angelantonio E, Boekholdt SM, Ouwehand W, Watkins H, Samani NJ, Saleheen D, Lawlor D, Reilly MP, Hingorani AD, Talmud PJ, Danesh J. Triglyceride Coronary Disease Genetics Consortium and Emerging Risk Factors Collaboration, et al. Lancet. 2010 May 8;375(9726):1634-9. doi: 10.1016/S0140-6736(10)60545-4. Lancet. 2010. PMID: 20452521 Free PMC article.
Lipoprotein(a) and risk of type 2 diabetes.
Mora S, Kamstrup PR, Rifai N, Nordestgaard BG, Buring JE, Ridker PM. Mora S, et al. Among authors: nordestgaard bg. Clin Chem. 2010 Aug;56(8):1252-60. doi: 10.1373/clinchem.2010.146779. Epub 2010 May 28. Clin Chem. 2010. PMID: 20511445 Free PMC article.
1,129 results